Moderna’s experimental vaccine prevents cancer recurrence, in ‘historic’ win for personalized medicine. Its stock soared.
MarketWatch · C · trust 31/100
The candidate is a combination of an mRNA therapeutic vaccine and Merck’s cancer drug Keytruda.
Read the original at MarketWatch →
Open in TruthVane →